SAB Biotherapeutics (SABS) Equity Ratio (2020 - 2025)
Historic Equity Ratio for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to 0.9.
- SAB Biotherapeutics' Equity Ratio rose 3118.01% to 0.9 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9, marking a year-over-year increase of 3118.01%. This contributed to the annual value of 0.59 for FY2024, which is 1391.8% down from last year.
- SAB Biotherapeutics' Equity Ratio amounted to 0.9 in Q3 2025, which was up 3118.01% from 0.4 recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Equity Ratio registered a high of 0.9 during Q3 2025, and its lowest value of 0.3 during Q3 2021.
- Over the past 5 years, SAB Biotherapeutics' median Equity Ratio value was 0.58 (recorded in 2022), while the average stood at 0.57.
- Per our database at Business Quant, SAB Biotherapeutics' Equity Ratio skyrocketed by 9441.02% in 2022 and then crashed by 4647.92% in 2025.
- SAB Biotherapeutics' Equity Ratio (Quarter) stood at 0.48 in 2021, then increased by 28.42% to 0.61 in 2022, then rose by 11.88% to 0.68 in 2023, then dropped by 13.92% to 0.59 in 2024, then skyrocketed by 53.14% to 0.9 in 2025.
- Its Equity Ratio was 0.9 in Q3 2025, compared to 0.4 in Q2 2025 and 0.56 in Q1 2025.